Such scenario contrasts with exceptional cases of effectiveness, due to the stringent addiction of cancer cells to a given oncogene, such as BCR-ABL in chronic myeloid leukaemia, ERBB2 in breast cancer, ERBB1 in non-small cell lung cancer, B-RAF in metastatic melanoma. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.